Skip to content
PaperFren

Metabolism

Do sugar-coated proteins feed Ewing sarcoma?

Vasileva E, Warren M, Triche TJ, et al. · eLife · 2022

Open access · cc by · source: Europe PMC

A zebrafish EWSR1-FLI1 model produced CD99+ small-round-cell tumors with MAPK/ERK on; blocking heparan sulfate with Surfen reduced ERK1/2 signaling and tumorigenicity in vitro and in vivo.

Study at a glance

Design
Animal / in-vitro — Cre-inducible human EWSR1-FLI1 zebrafish model of Ewing sarcoma plus in-vitro/in-vivo tests of the heparan sulfate antagonist Surfen
N
N=524 · Survival analysis in 524 EWSR1-FLI1 animals; controls included uninjected N=528, GFP N=328, Cre N=304; tumor incidence also scored in n=77 Cre-injected fish
Population
Wild-type zebrafish embryos/larvae expressing human EWSR1-FLI1, with supporting Ewing sarcoma cell assays
Outcome
SRBCT formation, MAPK/ERK activity, and whether Surfen lowers ERK signaling and tumorigenicity

Structured fields used in claim comparison tables when every cited study has a complete layer.

Key findings

EWSR1-FLI1 caused rapid, high-penetrance SRBCTs that expressed canonical targets and CD99. Tumor growth tracked MAPK/ERK activation linked to dysregulated ECM and HSPG catabolism. Surfen reduced ERK1/2 signaling and decreased tumorigenicity. Survival analysis used 524 EWSR1-FLI1 animals vs large control groups.

Methodology

Built Cre-inducible human EWSR1-FLI1 expression in wild-type zebrafish, characterized SRBCTs and ECM/heparan sulfate metabolism, then treated with the heparan sulfate antagonist Surfen in cells and fish.

Limitations

A zebrafish/cell study cannot yet show that Surfen is a safe human therapy; Ewing remains without an approved molecularly targeted drug from this paper alone.

How this study connects

Role on claims

Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.

Not yet placed on a claim. This paper has study layers, but no concept page yet cites it as support, challenge, or qualifier.

Related papers in this topic

Same topic cluster — not a recommendation engine.